Abstract
Background With up to 70% of adverse drug reactions (ADRs) having high genetic associations, the clinical utility of pharmacogenomics (PGx) has been gaining traction. Nala PGx Core™ is a multi-gene qPCR-based panel that comprises 18 variants and 2 CYP2D6 Copy Number markers across 4 pharmacogenes – CYP2C9, CYP2C19, CYP2D6 and SLCO1B1.
Objectives In this study, we validated the performance of Nala PGx Core™ against benchmark methods, on the Singaporean and Indonesian populations. Additionally, we examined the allele and diplotype frequencies across 5 major ethnic groups present in these populations namely, Indonesians, Chinese, Malays, Indians and Caucasians.
Methods Human gDNA samples, extracted from the buccal swabs of 246 participants, were tested on Nala PGx Core™ and two chosen benchmarks, Agena VeriDose® Core and CYP2D6 Copy Number Variation (CNV) Panel, and TaqMan® DME Genotyping Assays. Performance was evaluated based on assay robustness, precision and accuracy at the genotype- and diplotype-level.
Results Nala PGx Core™ demonstrated high genotype- and diplotype-level call rates of >97% and >95% respectively in CYP2D6, and 100% for CYP2C9, CYP2C19 and SLCO1B1. A precision rate of 100% was observed on both intra- and inter-precision studies. Variant-level concordance to the benchmark methods was ≥96.9% across all assays, which consequently resulted in a diplotype-level concordance of ≥94.7% across CYP2C9, CYP2C19 and CYP2D6. Overall, the allele frequencies of CYP2D6*10 and CYP2D6*36 were higher in our cohort as compared to previous records. Notably, CYP2D6 copy number variation (CNV) analysis demonstrated a CYP2D6 *10/*36 frequency of 26.5% amongst the Indonesian cohort.
Conclusion Nala PGx Core™ produced robust and accurate genotyping when compared to other established benchmarks. Furthermore, the panel successfully characterized alleles of clinical relevance in the Singaporean and Indonesian populations such as CYP2D6*10 and CYP2D6*36, suggesting its potential for adoption in clinical workflows regionally.
Competing Interest Statement
A.S.K., M.T., J.P., J.T., C.M., G., J.S.H., and A.I. are employees of Nalagenetics Pte Ltd. A.I. and A.L. has financial holdings in Nalagenetics Pte Ltd. Nalagenetics Pte Ltd and PT Nalagenetik Riset Indonesia are the license holders of Nala PGx Core.
Funding Statement
All expenses for this study were funded by Nalagenetics Pte Ltd, Singapore, and PT Nalagenetik Riset Indonesia.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board (IRB) approval was granted by the Parkway Independent Ethics Committee (Singapore) under IRB Reference Number PIEC/2019/021 and Siloam Hospitals Ethics Review Committee (Jakarta, Indonesia) under IRB Reference Number 001/EA/KEPKK/RSMRCCC/V/2019.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that supports the findings of this study are available as supplementary materials. Any additional data is available from the corresponding author upon reasonable request.
